Keyword: Lyrica

AbbVie’s Humira and Pfizer’s Lyrica remained in the top two spots for pharma TV ad spending in March, according to realtime TV ad tracker iSpot.tv.

​​​​​​​Debut ads helped drive list-toppers for pharma TV spend in February, with Ibrance, Otezla, Rexulti, Entresto and Eliquis entering the top 10.

Pfizer could be on the hook for £502 million in National Health Service spending on Lyrica if a patent appeal fails, according to a new study.

It’s a new year of TV ad spending in pharma, and AbbVie's Humira and Pfizer's Lyrica started with a bang at more than $35 million each last month.

After a rare decline last month, AbbVie's Humira reclaimed its title as top advertised drug on TV with more than $40 million in spending.

Bracing for generic competition to big-selling Lyrica, Pfizer has won FDA approval for a longer-lasting version that could help it defend sales.

AbbVie’s Humira was in an unfamiliar spot last month: second place.

AbbVie's Humira and Pfizer's Lyrica topped the pharma ad spending top 10 for August as J&J's Stelara surged with a new ad for its Crohn's indication.

In lowering their rating, analysts with Credit Suisse highlighted some concerns with Pfizer's business going forward.